powered by multi-dimensional cell engineering
SQZ® Biotechnologies Pipeline

Our pipeline spans multiple indications across diseases areas where there remains significant unmet patient need for safe and effective new therapies.
Through multi-dimensional cell engineering, these existing and possible therapeutic candidates offer the potential to turn a patient’s immune system on or off to address disease.

The JDRF T1D Fund has invested in SQZ Biotech on multiple occasions to help progress the T1D program.
SQZ® is a registered trademark of SQZ Biotechnologies Company. All rights reserved.